WINNIPEG, Manitoba, Sept. 26, 2024 (GLOBE NEWSWIRE) — Kane Biotech Inc. (TSX- V:KNE; OTCQB:KNBIF) (“Kane Biotech”, “Kane” or the “Company”) announces that the Company will be showcasing its revyve™ Antimicrobial Wound Gel and revyve™ Antimicrob
“These upcoming conferences will be a great opportunity for Kane to demonstrate the scientific benefits of the revyve™ product line to wound care practitioners and support our growing distribution network,” said Marc Edwards, President & CEO. “We’re committed to changing the wound care landscape and look forward to these meetings.” Read More
